Product
Soliramfetol
1 clinical trial
2 indications
Indication
GliomaIndication
GlioblastomaClinical trial
Open Label Safety Study of Solriamfetol to Promote Wakefulness and Improve Cognition and Quality of Life in Patients With Primary GliomasStatus: , Estimated PCD: 2024-07-01